Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
User tried topical fin, dut, min, tret, hydrocortisone, microneedling, nizoral, collagen, propidren supplements, and laser helmet for hair loss with slow progress. They ask if topical spironolactone is a safer, effective alternative to RU for suppressing testosterone and treating hair loss in men.
The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.
The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
The user is using a comprehensive hair loss prevention regimen including Dutasteride, RU58841, topical treatments, red light therapy, microneedling, and supplements like Nutrafol, while avoiding Minoxidil. They also supplement with vitamin D and zinc and plan to start testosterone replacement therapy (TRT) in January.
The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.
Federal funding for medical research in the U.S. has been halted, potentially delaying new treatments. Hair loss treatments like finasteride and minoxidil are unlikely to be impacted as they are typically funded by private companies.
The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.
The conversation is about a hair loss treatment regimen using high concentrations of natural ingredients: pumpkin seed oil, saw palmetto, rosemary and peppermint essential oils, and caffeine. The user also practices microneedling, scalp massage, and takes Nutrafol.
Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.
Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.
Finasteride may help stabilize hair loss, but regrowth at the temples is challenging and often requires additional treatments like minoxidil or a hair transplant. Users suggest patience and possibly combining treatments for better results.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
A user is exploring personalized topical formulations for hair loss from Roots By Genetics Art, specifically interested in the GA-5 Power Restore formulation containing dutasteride, minoxidil, and other ingredients. They seek opinions on the effectiveness and value of these products.
The user experienced significant hair regrowth using a nightly topical spray with 0.3% finasteride and 6% minoxidil, without side effects. Noticeable improvements were seen within three months, with continued progress over time.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.
The user has tried various treatments for hair loss, including finasteride, dutasteride, and oral minoxidil, but is considering a hair transplant due to insufficient progress. Some users suggest that the treatments have at least stabilized hair loss, and recommend consulting clinics for a potential hair transplant while continuing medication.
The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.